BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 27411517)

  • 1. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
    Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
    BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
    Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
    Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
    Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
    J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOX2 expression is regulated by BRAF and contributes to poor patient prognosis in colorectal cancer.
    Lundberg IV; Löfgren Burström A; Edin S; Eklöf V; Öberg Å; Stenling R; Palmqvist R; Wikberg ML
    PLoS One; 2014; 9(7):e101957. PubMed ID: 25010701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
    Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
    Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.
    Bae JM; Lee TH; Cho NY; Kim TY; Kang GH
    World J Gastroenterol; 2015 Feb; 21(5):1457-67. PubMed ID: 25663765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
    Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
    BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.
    Baba Y; Nosho K; Shima K; Freed E; Irahara N; Philips J; Meyerhardt JA; Hornick JL; Shivdasani RA; Fuchs CS; Ogino S
    Clin Cancer Res; 2009 Jul; 15(14):4665-73. PubMed ID: 19584150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20.
    Lee JA; Seo MK; Yoo SY; Cho NY; Kwak Y; Lee K; Kim JH; Kang GH
    Virchows Arch; 2022 Mar; 480(3):543-555. PubMed ID: 35029777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression.
    Landau MS; Kuan SF; Chiosea S; Pai RK
    Hum Pathol; 2014 Aug; 45(8):1704-12. PubMed ID: 24908142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway.
    Graule J; Uth K; Fischer E; Centeno I; Galván JA; Eichmann M; Rau TT; Langer R; Dawson H; Nitsche U; Traeger P; Berger MD; Schnüriger B; Hädrich M; Studer P; Inderbitzin D; Lugli A; Tschan MP; Zlobec I
    Clin Epigenetics; 2018 Sep; 10(1):120. PubMed ID: 30257705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
    Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
    J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
    Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
    Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDX2 Protein Expression in Colorectal Cancer and ItsCorrelation with Clinical and Pathological Characteristics, Prognosis, and Survival Rate of Patients.
    Asgari-Karchekani S; Karimian M; Mazoochi T; Taheri MA; Khamehchian T
    J Gastrointest Cancer; 2020 Sep; 51(3):844-849. PubMed ID: 31630373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
    Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
    Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer.
    Xu W; Zhu Y; Shen W; Ding W; Wu T; Guo Y; Chen X; Zhou M; Chen Y; Cui L; Du P
    J Int Med Res; 2019 May; 47(5):1829-1842. PubMed ID: 30616445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.